The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Dual BCMA/GPRC5D targeting CAR-T for MM
Carlos Fernandez de Larrea, MD, PhD, University of Barcelona, Barcelona, Spain, outlines a study evaluating whether upfront simultaneous targeting of BCMA plus an additional antigen such as G protein-coupled receptor class C group 5 member D (GPRC5D) can mitigate BCMA escape-mediated relapse in multiple myeloma (MM). Dr de Larrea explains that dual targeting strategies were explored in vivo in order to identify an optimal approach. Results show that a single bicistronic vector encoding two 4-1BB-containing CARs avoids the practical challenges of parallel manufacturing and uniquely may provide superior anti-MM efficacy. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
